Inactive Instrument

Mologen AG Xetra

Equities

MGNK

DE000A2LQ900

Biotechnology & Medical Research

MOLOGEN AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

April 16, 2019 at 11:40 am EDT

DGAP Total Voting Rights Announcement: MOLOGEN AG / Total Voting Rights Announcement
MOLOGEN AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

16.04.2019 / 17:36
Total Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of total number of voting rights

1. Details of issuer

MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany

2. Type of capital measure

	Type of capital measure	Date of status / date of effect
X	Conditional capital increase (Sec. 41 para. 2 WpHG)	31.03.2019
	Other capital measure (Sec. 41 para. 1 WpHG)

3. New total number of voting rights:

10.063.554

16.04.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	MOLOGEN AG
	Fabeckstraße 30
	14195 Berlin
	Germany
Internet:	www.mologen.com


End of News	DGAP News Service

800881 16.04.2019

Latest news about Mologen AG

Mologen AG Announces Updates on Phase III IMPALA Study; Provides Earnings Guidance for the Full Year 2019	19-08-14	CI
Mologen AG Announces Management Changes	19-03-27	CI
Mologen AG Announces Management Changes	18-08-01	CI
Mariola Soehngen Not to Renew Her Position as Member and Chief Executive Officer on the Board of Directors of Mologen AG Which Expires on 31 October 2018	18-04-20	CI
Mologen Reports Earnings Results for the Six Months of 2016; Provides Earnings Guidance for the Full Year of 2016	16-08-17	CI
Mologen AG Announces Progress in Clinical Studies; Announces Earnings Results for the First Quarter of 2016; Confirms Earnings Guidance for the Year 2016	16-05-12	CI
Mologen AG Reports Earnings Results for the Year 2015	16-03-21	CI
MOLOGEN AG Appoints Walter Miller as Member of the Executive Board and Chief Financial Officer with Effect from April 1, 2016	16-03-16	CI
Mologen AG Announces Extension of TEACH Study Based on Supportive First Study Results	16-03-14	CI
Mologen AG Supports Development Strategy of lefitolimod (MGN1703)	16-02-25	CI
MOLOGEN AG and the University of Texas MD Anderson Cancer Center Enter into Collaboration Agreement Relating to Phase I trial with MOLOGEN’s Immunomodulator Lefitolimod in Combination with the Immunotherapy Yervoy® in Patients with Advanced Solid Malignancies	16-01-19	CI
MOLOGEN AG Reaffirms Earnings Guidance Financial Year 2015	15-11-12	CI
Mologen AG(XTRA:MGN) dropped from S&P Global BMI Index	15-09-21	CI
Mologen AG Reports Earnings Results for the First Half of 2015	15-08-13	CI
MOLOGEN AG Announces Managements Changes	15-07-23	CI
Mologen Holding AG’s Equity Buyback announced on June 7, 2010 has expired.	15-06-06	CI
Aarhus University Hospital Initiates MGN1703 Study in HIV Patients	15-05-08	CI
MOLOGEN AG Presents Data Supporting Administration Scheme of MGN1703 at ITOC-2 Conference 2015	15-03-30	CI
Mologen Reports Earnings Results for the Year 2014	15-03-25	CI
Mologen AG Presents Subgroup Analysis from Impact Study and Design of Pivotal Impala Trial	15-01-19	CI
Mologen AG Provides Earnings Guidance for the Year of 2014; Announces Results of Clinical Development of the Cancer Immunotherapy MGN1703	14-11-13	CI
MOLOGEN Presents Preclinical Data on its EnanDIM Technology at 10th Annual Meeting of the Oligonucleotide Therapeutics Society	14-10-14	CI
Mologen AG Announces Initiation of Phase III IMPALA Study with Immunotherapy MGN1703 in Colorectal Cancer	14-09-11	CI
Mologen AG Receives First Approvals for Phase III Impala Colorectal Cancer Study	14-08-04	CI
Mologen AG Presents Immunological Data on Renal Cancer Therapy MGN1601 at CIMT	14-05-07	CI

Chart Mologen AG

Duration

Period

More charts

Company Profile

Mologen AG is a Germany-based company engaged in the biotechnology and medical research industry. The Company specializes in the research and development of drugs in the fields of oncology and infectious diseases. The Company develops medicines and vaccines on the basis of its MIDGE, dSLIM and EnanDIM platform technologies and through the use of its human, allogeneic tumor cell bank. Within the area of oncology, the Company develops Lefitolimod, which is intended to enable the patient's immune system to recognize the body's own cancer cells and fight them, MGN1601, which works like a therapeutic vaccination against cancer, as well as MGN1404, which is targeted at malignant melanoma. Within the area of infectious diseases, the Company develops deoxyribonucleic acid (DNA) vaccines against leishmaniasis and hepatitis B.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+43.29%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research